Who is sponsoring T4R?

T4R is sponsored by University of Leicester.

What drugs are being tested in T4R?

Interventions: Liraglutide, Liraglutide, Sulfonylurea or Pioglitazone, Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide.

Last reviewed 2020-01-29 · How we verify

A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Liraglutide vs. a Sulphonylurea (T4R)

NCT02292290 Phase 4 COMPLETED

Dual therapy with metformin and Liraglutide is more effective at helping people with established Type 2 Diabetes Mellitus (T2DM) observing Ramadan achieve a triple composite endpoint of weight reduction and/or maintenance and improved HaemaglobinA1c (HbA1c) and no severe hypoglycaemic events.

Details

Lead sponsor	University of Leicester
Phase	Phase 4
Status	COMPLETED
Enrolment	99
Start date	2011-04
Completion	2012-12

Conditions

Type 2 Diabetes

Interventions

Liraglutide
Liraglutide
Sulfonylurea or Pioglitazone
Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide

Primary outcomes

Composite — 12 weeks following post Ramadan cinical assessment
A composite endpoint of a reduction in weight, reduction/maintenance of HbA1c and elimination of severe hypoglycaemic (defined as hospital admission) events post intervention.

Countries

United Kingdom